It is correct if the therapy is targeting all stem cells. I have not understood clearly from the article but it seems the treatement is targeting "living cells". Once all your 'fixed' cells have been renewed you would need another round of treatement.
I think most cells are made by mitosis and don't come from stem cells.
Here's a screenshot of the explanation I received when I was invited on the trial -https://i.imgur.com/H329Vgv.jpg
> "By using BMN 270 to provide the functional genes, it is expected that you may not require treatment for Haemophilia A, as often or at all."
I don't really want to upload the whole Participant Information Sheet because it contains some of the doctor's personal details.
The increase in the pipeline of gene therapies just in the past few months has been incredible.
Here are the ones I'm tracking: BioMarin valoctocogene roxaparvovec (BMN-270) Spark SPK-8011 Sangamo (Pfizer) SB-525 Bioverativ BIVV-001 Shire SHP-654 (BAX-888)
Its quite incredible though, there's only a few thousand people in the UK with haemophilia - this trial just cured like 0.5% of them
Thanks again for the info. Best of luck!
> As for the liver, the human body's detoxifier, its cells' lives are quite short - an adult human liver cell has a turnover time of 300 to 500 days.
https://www.timeshighereducation.com/news/life-span-of-human...
So I think it must be targeting the stem cells or this wouldn't last more than a year or two? EDIT: See Chriky's comment.
"""After infusion, antibodies to AAV5 were detected in all the tested participants, but no T-cell–mediated immune responses to AAV5 capsid proteins were detected, and neutralizing antibodies to factor VIII did not develop in any participants. The absence of factor VIII inhibitors during more than 1 year of follow-up underscores the safety of AAV5-hFVIII-SQ. As has been observed in similar clinical trials of vector gene transfer,13,19,29 vector DNA was detected in various biologic fluids obtained from all the participants (see the Vector Shedding–Discussion section in the Supplementary Appendix). The possibility of vector integration was not assessed. The protocol was not designed to measure whether AAV5 infection was present in family members or close contacts, and ethics approval was not sought to pursue this question. The two viral genes within AAV5 have been replaced by factor VIII, and AAV5 requires another virus such as an adenovirus for a productive infection."""
This is a surprising finding because normally AAV5 leads to an immune response in this kind of treatment, although symptoms are mild and the virus in general is not considered pathogenic.
The mechanism of integration is described in detail in the wikipedia page. https://en.wikipedia.org/wiki/Adeno-associated_virus
I think if this worked as intended, no additional treatment is required.